Tag Archives: Rocket Pharmaceuticals

Cowen & Co. Believes Rocket Pharmaceuticals (NASDAQ: RCKT) Won’t Stop Here

In a report issued on August 5, Yaron Werber from Cowen & Co. maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The company’s shares closed last Friday at $26.46, close to its 52-week high of $27.73. According

LifeSci Capital Believes Rocket Pharmaceuticals (NASDAQ: RCKT) Won’t Stop Here

In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), with a price target of $35.00. The company’s shares closed last Wednesday at $25.26, close to its 52-week high

Rocket Pharmaceuticals (RCKT) Gets a Buy Rating from Oppenheimer

In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), with a price target of $43.00. The company’s shares closed last Monday at $22.17. According to TipRanks.com, DeGeeter is a

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (NASDAQ: RCKT) and PerkinElmer (NYSE: PKI)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rocket Pharmaceuticals (RCKT – Research Report) and PerkinElmer (PKI – Research Report). Rocket Pharmaceuticals (RCKT) Chardan Capital analyst Geulah Livshits reiterated a Buy rating on

William Blair Keeps a Buy Rating on Rocket Pharmaceuticals (RCKT)

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The company’s shares closed last Wednesday at $17.13. According to TipRanks.com, Prasad is a 5-star analyst with an average

Rocket Pharmaceuticals (RCKT) Receives a Buy from William Blair

William Blair analyst Raju Prasad maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today. The company’s shares closed last Thursday at $13.90. According to TipRanks.com, Prasad is a 4-star analyst with an average return of 3.5% and